Morphic Holding Stock News

89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.

Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023.

Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.85 per share a year ago.

Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price

Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.

WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chro

WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chron

Morphic Holding has curled up off recent lows and caught a strong bid into the new year. It broke out above its longer-term resistance level and has finished above this mark for the last 3-weeks of tr

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chron

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the

Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric

Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Strs Ohio decreased its holdings in shares of Morphic Holding, Inc. (NASDAQ:MORF) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,800 shares of the company’s stock after selling 200 shares during the period. Strs Ohio’s holdings in Morphic were worth $555,000 at the […] The post Morphic Holding, Inc. (NASDAQ:MORF) Shares Sold by Strs Ohio appeared first on ETF Daily News .

Royal Bank of Canada boosted its position in Morphic Holding, Inc. (NASDAQ:MORF) by 2,040.9% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 24,085 shares of the companys stock after buying an additional 22,960 shares during the period. Royal Bank of Canadas holdings in Morphic were worth $1,382,000 as of its most recent []